Topical Timolol for Small Superficial Infantile Hemangiomas
For small, thin, superficial infantile hemangiomas, apply topical timolol maleate 0.5% gel-forming solution or drops twice daily to the lesion, continuing treatment for at least 6 months and often until 12 months of age. 1
Indication and Patient Selection
Topical timolol is specifically indicated for:
- Thin and/or superficial hemangiomas (ideally <1 mm thick)
- Small lesions (typically <2 cm in diameter)
- Intact skin (use with extreme caution if ulcerated due to increased systemic absorption risk) 1
Exclusions: Do not use topical timolol as monotherapy for large, significantly elevated, deep, or life-threatening hemangiomas—these require systemic propranolol 1.
Treatment Regimen
Dosing Protocol
- Formulation: Timolol maleate 0.5% ophthalmic gel-forming solution or drops
- Application: Apply topically to the lesion twice daily (every 12 hours)
- Duration: Minimum 6 months, typically continued until 12 months of age, occasionally longer 1, 2
- Timing: Initiate early (ideally by 1 month of age) during the proliferative phase for optimal results, as most rapid growth occurs between 1-3 months of age 1
Application Technique
Apply the medication directly to the hemangioma surface. The evidence shows best responses in superficial lesions <1 mm thick versus mixed or deep hemangiomas 1.
Expected Outcomes and Timeline
Response rates:
- Improvement observed in 70% of patients at 1-3 months 1
- 92.3% improvement with longer treatment duration 1
- Total response rate of 82.8% in observational studies 2
- Color change typically appears first, often by week 4 3, 4
- Size reduction becomes significant by weeks 16-24 4
The evidence shows that early treatment (before 6 months of age) yields superior results, with 98% effectiveness when started before 1 year versus 69% when initiated between ages 1-5 years 5.
Safety Profile and Monitoring
Adverse Effects
Local reactions (4.7% of patients): 6
- Skin irritation (most common—nearly half of all adverse events)
- Scaling, pruritus
- Local ulceration
Systemic effects (1.2-3.4% of patients): 1, 6
- Bronchospasm (rare but most concerning)
- Sleep disturbances, insomnia
- Cold extremities
- Bradycardia (rare)
- No cardiovascular events reported in the largest cohort of 731 patients 1
Critical Safety Considerations
Exercise heightened caution in:
- Preterm infants (higher risk of systemic absorption)
- Ulcerated hemangiomas (compromised skin barrier increases absorption)
- Large treatment areas (greater surface area for absorption)
- Very young infants (<2 months) 1, 7, 6
Important pharmacokinetic warning: Timolol is detected in blood or urine in 83% of treated infants, indicating systemic absorption occurs despite topical application 7. However, serum levels remain low (median 0.16 ng/mL) and are generally safe for small hemangiomas 7. Timolol is significantly more potent than propranolol and bypasses first-pass liver metabolism, necessitating caution 1.
Monitoring Protocol
While the AAP guidelines don't mandate specific vital sign monitoring for topical timolol (unlike oral propranolol), prudent practice includes:
- Baseline assessment before initiation
- Parental education on signs of bronchospasm, sleep disturbances, or lethargy
- Clinical follow-up at 2-4 weeks initially, then monthly to assess response
- No routine cardiovascular monitoring required for small superficial lesions with intact skin 4
When to Escalate Treatment
Transition to oral propranolol if:
- Hemangioma extends deep into dermis during treatment
- Inadequate response after 2-3 months
- Lesion characteristics change (becomes thicker, deeper, or rapidly proliferates)
- Development of complications (ulceration, functional impairment) 1
Only 7% of patients in large studies required subsequent systemic β-blocker therapy after topical timolol 1, indicating good efficacy for appropriately selected lesions.
Practical Considerations
Shared decision-making is essential: Parents play a significant role in deciding whether to treat small superficial lesions, as many will involute spontaneously. Discuss the modest benefit in hemangioma clearance against the low risk of adverse effects and cost of medication 1.
Contraindications to avoid:
- Do not use on mucosal surfaces
- Avoid if concomitant systemic propranolol is being used (risk of excessive β-blockade)
- Use extreme caution with asthma or reactive airway disease 7, 4
The evidence strongly supports topical timolol as a safe, effective first-line option for small, thin, superficial infantile hemangiomas, with the AAP providing a Grade B moderate recommendation for this indication 1.